Search research articles
Contact Us
Filters
Showing results (181-190 of 272) with videos related to
Page
of 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2007
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma
Ajay K Gopal, Joseph G Rajendran, Ted A Gooley, et al.
Cancer Research
|
January 2, 2009
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia
John M Pagel, Dana C Matthews, Aimee Kenoyer, et al.
Cancer Research
|
September 28, 2014
In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model
Ethan R Balkin, Aimee Kenoyer, Johnnie J Orozco, et al.
Cancer Research
|
February 27, 2009
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211
Hirohisa Nakamae, D Scott Wilbur, Donald K Hamlin, et al.
Blood
|
November 29, 2007
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy
John M Pagel, Nathan Hedin, Lacey Drouet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2013
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial
Julie M Vose, Shelly Carter, Linda J Burns, et al.
Blood
|
August 10, 1999
Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
D C Matthews, F R Appelbaum, J F Eary, et al.
The Lancet. Haematology
|
February 4, 2018
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study
Paul M Barr, Hongli Li, W Richard Burack, et al.
Human Gene Therapy
|
August 10, 2007
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains
Jinjuan Wang, Michael Jensen, Yukang Lin, et al.
Bioconjugate Chemistry
|
July 6, 2010
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants
D Scott Wilbur, Steven I Park, Ming-Kuan Chyan, et al.
Page
of 28
Search research articles
Search
Showing results (181-190 of 272) with videos related to
Sort By:
Page
of 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2007
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma
Ajay K Gopal, Joseph G Rajendran, Ted A Gooley, et al.
Cancer Research
|
January 2, 2009
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia
John M Pagel, Dana C Matthews, Aimee Kenoyer, et al.
Cancer Research
|
September 28, 2014
In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model
Ethan R Balkin, Aimee Kenoyer, Johnnie J Orozco, et al.
Cancer Research
|
February 27, 2009
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211
Hirohisa Nakamae, D Scott Wilbur, Donald K Hamlin, et al.
Blood
|
November 29, 2007
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy
John M Pagel, Nathan Hedin, Lacey Drouet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2013
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial
Julie M Vose, Shelly Carter, Linda J Burns, et al.
Blood
|
August 10, 1999
Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
D C Matthews, F R Appelbaum, J F Eary, et al.
The Lancet. Haematology
|
February 4, 2018
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study
Paul M Barr, Hongli Li, W Richard Burack, et al.
Human Gene Therapy
|
August 10, 2007
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains
Jinjuan Wang, Michael Jensen, Yukang Lin, et al.
Bioconjugate Chemistry
|
July 6, 2010
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants
D Scott Wilbur, Steven I Park, Ming-Kuan Chyan, et al.
Page
of 28